Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Arcutis Biotherapeutics Inc’s stock clocked out at $30.96, up 0.75% from its previous closing price of $30.73. In other words, the price has increased by $0.75 from its previous closing price. On the day, 1.92 million shares were traded. ARQT stock price reached its highest trading level at $31.105 during the session, while it also had its lowest trading level at $30.3825.
Ratios:
To gain a deeper understanding of ARQT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.28 and its Current Ratio is at 3.50. In the meantime, Its Debt-to-Equity ratio is 0.72 whereas as Long-Term Debt/Eq ratio is at 0.71.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on July 25, 2025, initiated with a Neutral rating and assigned the stock a target price of $18.
On December 30, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $19.
On August 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.Jefferies initiated its Buy rating on August 28, 2024, with a $15 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 24 ’25 when LIN SUE-JEAN sold 25,272 shares for $30.78 per share. The transaction valued at 777,956 led to the insider holds 26,735 shares of the business.
Watanabe Todd sold 48,945 shares of ARQT for $1,485,755 on Nov 24 ’25. The insider now owns 740,537 shares after completing the transaction at $30.36 per share. On Nov 21 ’25, another insider, Watanabe Todd, who serves as the insider of the company, sold 1,055 shares for $30.00 each. As a result, the insider received 31,650 and left with 793,838 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 3792358144 and an Enterprise Value of 3715064320. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.93 while its Price-to-Book (P/B) ratio in mrq is 23.56. Its current Enterprise Value per Revenue stands at 11.685 whereas that against EBITDA is -111.937.
Stock Price History:
The Beta on a monthly basis for ARQT is 1.68, which has changed by 1.3742332 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, ARQT has reached a high of $31.09, while it has fallen to a 52-week low of $10.57. The 50-Day Moving Average of the stock is 38.12%, while the 200-Day Moving Average is calculated to be 86.49%.
Shares Statistics:
It appears that ARQT traded 2.29M shares on average per day over the past three months and 3059400 shares per day over the past ten days. A total of 120.29M shares are outstanding, with a floating share count of 107.41M. Insiders hold about 12.31% of the company’s shares, while institutions hold 96.51% stake in the company. Shares short for ARQT as of 1763078400 were 13717750 with a Short Ratio of 5.98, compared to 1760486400 on 14276026. Therefore, it implies a Short% of Shares Outstanding of 13717750 and a Short% of Float of 13.76.
Earnings Estimates
As of right now, 7.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.03, with high estimates of $0.12 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.15 and -$0.31 for the fiscal current year, implying an average EPS of -$0.15. EPS for the following year is $0.45, with 7.0 analysts recommending between $0.78 and $0.25.
Revenue Estimates
In. The current quarter, 6 analysts expect revenue to total $109.83M. It ranges from a high estimate of $112.6M to a low estimate of $107M. As of. The current estimate, Arcutis Biotherapeutics Inc’s year-ago sales were $71.36MFor the next quarter, 6 analysts are estimating revenue of $98.23M. There is a high estimate of $102.31M for the next quarter, whereas the lowest estimate is $94.6M.
A total of 8 analysts have provided revenue estimates for ARQT’s current fiscal year. The highest revenue estimate was $361.3M, while the lowest revenue estimate was $353.6M, resulting in an average revenue estimate of $357.45M. In the same quarter a year ago, actual revenue was $196.54MBased on 8 analysts’ estimates, the company’s revenue will be $467.32M in the next fiscal year. The high estimate is $470.1M and the low estimate is $462M.
